Alpha Cancer Technologies

Alpha Cancer Technologies Inc. (ACT) is a private clinical-stage biotechnology company with an immunotherapy, treatment, and immune modulation platform under development. The company's pharmaceutical products utilize ACT's patented recombinant human alpha-fetoprotein (AFP or ACT-101). ACT’s immunotherapy products target the AFP receptor, which is uniquely expressed on nearly all solid and liquid tumors and immunosuppressive cells but not on normal cells. This approach leverages next-generation ADC technology, offering significantly lower toxicity and improved efficacy compared to traditional chemotherapy and other targeted therapies.